A bit about me
I am passionate about supporting our clients in the achievement of appropriate reimbursement for highly innovative medical solutions, especially in therapeutic fields covering some of the most devastating medical conditions: it is important to emphasise the worth of new drug developments to encourage future inventions, which are crucial to overcome current medical unmet needs.
Career highlights
Steven joined the German subdivision of Kintiga in March 2021 and has a study background in molecular biology. He worked 4 years in the field of genomic research, before entering the new working path in pharmaceutical market access.
Initially starting with the compilation and strategic support of AMNOG-dossiers, Steven meanwhile leads market access projects covering the whole HTA portfolio, ranging from early risk assessments, price scenario modelling, dossier-strategy, oral hearing support and the full strategy support during price negotiations.
Thereby, Steven gained experience in the leadership of projects covering all crucial steps in German market access, developing a holistic view on all essential steps required to achieve appropriate reimbursement.
In his past projects, ranging from rare disease to oncology to female health indications, Steven took active participation in oral hearings and advice meetings at the G-BA and during price negotiations with the GKV-SV as an integrated member of the clients dossier, oral hearing and negotiation teams.
Amongst his project highlights were the successful lead and coordination of AMNOG dossier projects, that required submissions under full support within timelines of just 4.5 and 3 months, respectively. Further he took action in the early development phase of automated; AI-assisted data description tools.
Expertise
- German HTA policy, processes, and methods
- German Market Access strategy development
- Price strategy
- Medical Writing and Dossier Strategy
- Active support in G-BA advice meetings, oral hearings and price negotiations with the GKV-SV
